DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. The post Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried appeared first on Investor's Business Daily.
Dexcom receives FDA warning letter for two U.S. manufacturing facilities
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down nearly 7% after the bell.
DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of Investor Relations Conference Call Participants Jayson Bedford - Raymond James Jayson Bedford Good morning. Welcome to the 46th Annual Raymond James Institutional Investors Conference.
3 Growth Stocks to Buy and Hold Forever
The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and profits, they become more valuable, and investors will be willing to pay more for them.
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
DexCom Analysts Increase Their Forecasts After Q4 Earnings
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by.
DexCom: Revenue Up, EPS Misses Mark
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion.
